Companion Diagnostics Market worth $9.9 billion by 2026 - Exclusive Report by MarketsandMarkets™

CHICAGO, Feb. 8, 2022 /PRNewswire/ -- According to the new market research report "Companion Diagnostics Market by Product (Assays, Kits, Software & Services), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Blood, Lung, Colorectal Cancer, Neurology Diseases), End User (Pharma Companies, CROs), Region - Global Forecast to 2026", published by MarketsandMarkets™, the global Companion Diagnostics Market is projected to reach USD 9.9 billion by 2026 from USD 5.5 billion in 2021, at a CAGR of 12.6%.

Browse in-depth TOC on "Companion Diagnostics Market"
322 – Tables
51 – Figures
331 – Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=155571681

The policy programs to provide effective care to patients with cancer, high drug development activity, structured regulatory framework in the region, and large patient pool undergoing advanced medical testing. Emerging economies such as China, Japan, and India are providing lucrative opportunities for the players operating in the companion diagnostics market.

The assays, kits & reagents segment accounted for the largest share of the companion diagnostics market, by product & service segment, in 2020

The companion diagnostics market is segmented into assays, kits & reagents, and software & services. The assays, kits & reagents accounted for the largest share of the companion diagnostics market in 2020, mainly due to the availability of a wide range of products and increasing use of assays and kits in different therapeutic areas.

PCR segment to register the highest growth rate during the forecast period

The companion diagnostics market is segmented into polymerase chain reaction (PCR), next-generation sequencing (NGS), in situ hybridization (ISH), immunohistochemistry (IHC), and other technologies. In 2020, the PCR segment accounted for the largest share of the companion diagnostics market. Factors such as the ease of use and widespread availability of PCR kits & reagents in companion diagnostic testing, and growing applications of PCR in the high-throughput detection of mutants with a limited or low allele frequency of genes.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=155571681

Cancer segment to register the highest growth rate during the forecast period

The companion diagnostics market is segmented into cancer, cardiovascular diseases (CVDs), neurological diseases, infectious diseases, and other indications (inflammatory and inherited diseases, among others). In 2020, the cancer segment accounted for the largest share of the companion diagnostics market. Factors such as growing role of companion diagnostics in the personalized medicine treatment for cancer, and increasing utility of biomarkers in the diagnosis of cancer.

The pharmaceutical & biotechnology companies segment accounted for the largest share of the companion diagnostics market, by end user segment, in 2020

Based on end user, the companion diagnostics market is segmented into pharmaceutical & biotechnology companies, reference laboratories, CROs, and other end users (including physician & hospital laboratories, and academic medical centers). In 2020, pharmaceutical & biotechnology companies accounted for a larger share of the companion diagnostics market. The growing use of companion diagnostics owing to their increasing prominence in drug development, and the increasing importance of companion diagnostic biomarkers.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=155571681

North America is the largest regional market for companion diagnostics market

The global companion diagnostics market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the companion diagnostics market. The North American companion diagnostics market growth can be attributed to the presence of many leading companion diagnostics vendors & national clinical laboratories, the easy accessibility to technologically advanced devices and instruments, and the highly developed healthcare system in the US and Canada.

The major players operating in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (US), Qiagen N.V. (Germany), Thermo Fisher Scientific, Inc. (US), Abbott Laboratories, Inc. (US), Almac Group (UK), Danaher Corporation (US), Illumina Inc. (US), bioMérieux SA (France), Myriad Genetics, Inc. (US), Sysmex Corporation (Japan), Abnova Corporation (Taiwan), Guardant Health, Inc. (US), ICON Plc (Ireland), BioGenex Laboratories, Inc. (US), Invivoscribe Technologies (US), ArcherDX, Inc. (US), NG Biotech (France), Q² Solutions (US), Amoy Diagnostics Co., Ltd. (China), Abacus Diagnostica Oy (Finland), Asuragen Inc. (US), SAGA Diagnostics (Sweden), Meso Scale Diagnostics, LLC. (US), and Creative Biolabs (US).

Browse Adjacent Markets: Medical Devices Market Research Reports & Consulting

Browse Related Reports:

Molecular Diagnostics Market by Product & Service (Reagents, Kits, PoC & Tabletop Instruments), Application (COVID-19, Hepatitis, HAI, HIV, Oncology, Genetic Tests), Technology (PCR, NGS, ISH), End User (Hospitals, Diagnostic Labs)-Global Forecast to 2026

https://www.marketsandmarkets.com/Market-Reports/molecular-diagnostic-market-833.html

Cancer Diagnostics Market by Product (Consumables (Anitibodies, Probes), Instruments (Pathology Instruments, Imaging Instruments, Biopsy), Technology (IVD Testing), Application (Breast Cancer, Lung Cancer), End User (Hospitals)- Global Forecasts to 2026

https://www.marketsandmarkets.com/Market-Reports/cancer-diagnostics-market-186559121.html

About MarketsandMarkets™ 

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/companion-diagnostics-market.asp
Visit Our Web Site: https://www.marketsandmarkets.com
Content Source: https://www.marketsandmarkets.com/PressReleases/companion-diagnostics.asp

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg